Intravitreal Bevacizumab and Low Fluence Photodynamic Therapy

University of Campania Luigi Vanvitelli16 enrolled

Overview

The purpose of this study is to report the treatment effect and safety of combined intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) with verteporfin using a reduced (RF) light fluence rate, in choroidal neovascularization (CNV) secondary to pathologic myopia.

In this retrospective interventional case series, 16 patients with myopic CNV were included. All patients were treated with 1.25 mg of intravitreal bevacizumab followed by RF-PDT (25 J/cm²), 2 days later. All patients were previously treated with IVB monotherapy and active leaking of CNV occurred 90 to 120 days after the treatment. Best-corrected visual acuity (BCVA-ETDRS), foveal thickness (FT) on optical coherence tomography (OCT), and fluorescein and indocyanine green angiographic (FA; ICG) findings were recorded. Follow-up evaluations were carried out for 12 months.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Myopia

Interventions

Combination therapy "IVB + rf-PDT"DRUG

low-fluence photodynamic therapy combined with intravitreal bevacizumab

Eligibility

Sex: ALLMin age: 35 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Myopic CNV, CNV leakage Exclusion Criteria: * CNV not associated with high myopia * No activity of CNV

Locations (1)

Ophthalmology Department SUN

Napoli, Napoli, Italy

Outcomes

Primary Outcomes

BCVA improved

Time frame: 6 months

Secondary Outcomes

no CNV leakage

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.